On July 31, the Shanghai Stock Exchange officially accepted the IPO application of Zhuhai Tainuo Mabpharm Co., Ltd. for listing on the STAR Market, marking the company as the first to be successfully approved under the newly revived fifth set of listing standards. Founded in 2015, Tainuo Mabpharm specializes in innovative biopharmaceuticals and boasts investments from seasoned and professional institutional investors.